T. Rowe Price Associates
VRDN icon

T. Rowe Price Associates’s Viridian Therapeutics VRDN Stock Holding History

T. Rowe Price Associates’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106M Buy
5,748,410
+2,542,375
+79% +$41M 0.01% 685
2026
Q1 		$62.7M Sell
3,206,035
-233,379
-7% -$6.93M 0.01% 716
2025
Q4 		$107M Buy
3,439,414
+1,021,310
+42% +$28M 0.01% 616
2025
Q3 		$52.2M Sell
2,418,104
-477,161
-16% -$8.61M 0.01% 799
2025
Q2 		$40.5M Buy
2,895,265
+1,207,136
+72% +$16.4M ﹤0.01% 784
2025
Q1 		$22.8M Buy
1,688,129
+361,318
+27% +$6.15M ﹤0.01% 925
2024
Q4 		$25.4M Buy
1,326,811
+1,281,799
+2,848% +$27.9M ﹤0.01% 934
2024
Q3 		$1.02M Buy
45,012
+593
+1% +$9.7K ﹤0.01% 1960
2024
Q2 		$578K Buy
44,419
+13,050
+42% +$181K ﹤0.01% 2134
2024
Q1 		$550K Buy
31,369
+5,429
+21% +$105K ﹤0.01% 2171
2023
Q4 		$565K Sell
25,940
-585
-2% -$9.23K ﹤0.01% 2126
2023
Q3 		$407K Buy
26,525
+2,580
+11% +$49.2K ﹤0.01% 2212
2023
Q2 		$570K Buy
23,945
+1,286
+6% +$33K ﹤0.01% 2062
2023
Q1 		$577K Sell
22,659
-2,235
-9% -$71.7K ﹤0.01% 2045
2022
Q4 		$727K Buy
24,894
+7,340
+42% +$169K ﹤0.01% 1954
2022
Q3 		$361K Buy
+17,554
New +$316K ﹤0.01% 2295

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates's VRDN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Viridian Therapeutics (VRDN) stake by 79% in Q2 2026, buying an estimated $41M and bringing the position to 5,748,410 shares worth $106M. The position accounts for 0.01% of the portfolio, ranked #685.

T. Rowe Price Associates first reported a position in VRDN in Q3 2022 and has held it in 16 quarters since. The position peaked at $107M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • T. Rowe Price Associates held 5,748,410 shares of Viridian Therapeutics worth $106M as of Q2 2026.
  • T. Rowe Price Associates bought 2,542,375 Viridian Therapeutics shares in Q2 2026, an estimated $41M.
  • Viridian Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #685 holding.
  • T. Rowe Price Associates first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • T. Rowe Price Associates's Viridian Therapeutics position peaked at $107M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.